P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

Bibliographic Details
Main Authors:	Cohen, R, Bhayat, F, Blake, A, Travis, S
Format:	Conference item
Published:	Oxford University Press 2019

Similar Items

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
by: Bhayat, F, et al.
Published: (2017)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
by: Travis, S, et al.
Published: (2018)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
by: Bhayat, F, et al.
Published: (2017)

The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
by: Cohen, R, et al.
Published: (2019)

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
by: Card, T, et al.
Published: (2019)

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
by: Card, T, et al.
Published: (2019)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
by: Feagan, B, et al.
Published: (2017)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
by: Feagan, BG, et al.
Published: (2018)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
by: Feagan, B, et al.
Published: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
by: Bye, W, et al.
Published: (2017)

Vedolizumab for the treatment of chronic pouchitis
by: Travis, S, et al.
Published: (2023)

Introducing vedolizumab to clinical practice: who, when and how?
by: Bryant, R, et al.
Published: (2015)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
by: Pulusu, S, et al.
Published: (2018)

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
by: Williamson, K, et al.
Published: (2018)

The concomitants of conspiracy concerns
by: Freeman, D, et al.
Published: (2017)

24.500 Other Minds, Spring 2003
by: Byrne, Alex
Published: (2023)

Concomitants of paranoia in the general population.
by: Freeman, D, et al.
Published: (2011)

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
by: Lynch, K, et al.
Published: (2019)

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
by: McGregor, CG, et al.
Published: (2021)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
by: Coates, LC, et al.
Published: (2016)

Fracture risk in patients receiving concomitant bisphosphonate and proton pump inhibitors or bisphosphonates alone: The UK general practice research database
by: de Vries, F, et al.
Published: (2008)

A case of Kawasaki Disease with concomitant leptospirosis
by: Foo, Caleb Chuan Yao, et al.
Published: (2021)

Concomitant bacteremia in adults with severe falciparum malaria
by: Phu, NH, et al.
Published: (2020)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Post-marketing studies: Ensuring the safety of diabetes drugs
by: Gough, S
Published: (2005)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, LC, et al.
Published: (2022)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
by: Coates, L, et al.
Published: (2022)

More than 1,500 first-year undergraduates received KADS1M
by: UMP, PNC

Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.
by: Braden, B, et al.
Published: (2012)

Concomitant bullous pemphigoid and neurological disease: an immunological association?
by: Taghipour, K, et al.
Published: (2008)

Co-Movement of Covid-19, The S&P 500 and Stock Markets in ASEAN: A Wavelet Coherence Analysis
by: Lee, Zhun Hoong, et al.
Published: (2022)

Co-movement of covid-19, the S&P 500 and stock markets in ASEAN: A wavelet coherence analysis
by: Lee Zhun Hoong, et al.
Published: (2022)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
by: Coates, L, et al.
Published: (2017)

Safety profile of remifentanil: A post-marketing study in Indonesia
by: Thobari, Jarir At, et al.
Published: (2022)

17 university students receive RM500 aid from Larry Sng Education Fund
by: Borneo Post, (KK)
Published: (2013)

Palladium-Catalyzed Alkynylation and Concomitant ortho Alkylation of Aryl Iodides
by: Lei, Chuanhu, et al.
Published: (2016)

Palladium-Catalyzed Heteroarylation and Concomitant ortho-Alkylation of Aryl Iodides
by: Lei, Chuanhu, et al.
Published: (2016)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)